AZN.L - AstraZeneca PLC

LSE - LSE Delayed Price. Currency in GBp
6,317.00
+44.00 (+0.70%)
At close: 4:35PM GMT
Stock chart is not supported by your current browser
Previous Close6,273.00
Open6,284.00
Bid6,200.00 x 6100
Ask6,480.00 x 13000
Day's Range6,254.26 - 6,432.48
52 Week Range4,544.50 - 6,432.48
Volume2,422,820
Avg. Volume2,356,266
Market Cap80.024B
Beta (3Y Monthly)1.27
PE Ratio (TTM)33.07
EPS (TTM)191.00
Earnings DateFeb 14, 2019
Forward Dividend & Yield2.02 (3.23%)
Ex-Dividend Date2018-08-09
1y Target Est79.54
  • This Recent Big Pharma Breakout Spiked Again On A $1.5 Billion Deal
    Investor's Business Daily2 days ago

    This Recent Big Pharma Breakout Spiked Again On A $1.5 Billion Deal

    AstraZeneca stock jumped Tuesday after the U.K.-based pharma giant said it would sell the U.S. rights to infant respiratory drug for $1.5 billion.

  • AstraZeneca to Sell US Rights of Lung Infection Drug to Sobi
    Zacksyesterday

    AstraZeneca to Sell US Rights of Lung Infection Drug to Sobi

    AstraZeneca (AZN) to sell U.S. rights of Synagis to Sobi for an upfront consideration of $1.5 billion as it streamlines its portfolio

  • Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA
    Zacksyesterday

    Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA

    PARP inhibitor makers get a boost following priority review for AstraZeneca???s (AZN) label expansion application for Lynparza as a first-line maintenance treatment for ovarian cancer.

  • AstraZeneca (AZN): Are Hedge Funds Right to be Bearish?
    Insider Monkey2 days ago

    AstraZeneca (AZN): Are Hedge Funds Right to be Bearish?

    Does AstraZeneca plc (ADR) (NYSE:AZN) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and invest millions of dollars on research activities, so it is no wonder why they tend to generate millions in profits […]

  • AstraZeneca's Lynparza Gets Priority Review in 1st Line Use
    Zacks2 days ago

    AstraZeneca's Lynparza Gets Priority Review in 1st Line Use

    AstraZeneca (AZN) and partner Merck's sNDA looking for label expansion of Lynparza in the first-line setting gets FDA's priority review.

  • $1.5B deal: AstraZeneca sells U.S. rights to respiratory medicine
    American City Business Journals2 days ago

    $1.5B deal: AstraZeneca sells U.S. rights to respiratory medicine

    AstraZeneca's deal to sell the U.S. rights to Synagis to a Swedish biopharmaceutical company is expected to be finalized early next year.

  • AstraZeneca Keeps Pruning Drugs in $1.5 Billion Sale to Sobi
    Bloomberg3 days ago

    AstraZeneca Keeps Pruning Drugs in $1.5 Billion Sale to Sobi

    Sobi, officially Swedish Orphan Biovitrum AB, also gained the right to share the U.S. profits and losses on a potential new medicine, which Astra is developing with Sanofi, that targets the same lung virus Synagis treats, the Cambridge, England-based company said in a statement. Chief Executive Officer Pascal Soriot has been paring back Astra’s portfolio, selling the rights to fading blockbusters such as Nexium for reflux as a new crop emerges, led by Imfinzi and other cancer drugs.

  • The Wall Street Journal3 days ago

    [$$] European Corporate Roundup

    AG said earnings fell sharply in the third quarter, in part as a result of a one-off gain booked in the prior year, while the number of glyphosate-related lawsuits it faces rose. Aftertax profit at the German chemical maker was 2.89 billion euros ($3.26 billion) compared with EUR3.88 billion a year earlier. DCC PLC said pretax profit in the first half of fiscal 2019 rose 17% and it continues to expect the full year to see more profit growth.

  • Reuters3 days ago

    Sobi buys rights to AstraZeneca infant drug for $1.5 bln upfront

    AstraZeneca has taken another step to refocus on priority drugs by selling U.S. rights to a treatment for infant lung infections to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion. Around 130 AstraZeneca staff will transfer to Sobi as the Swedish company, widely known as Sobi, takes over marketing of the treatment Synagis in the United States.

  • Reuters3 days ago

    AstraZeneca sells infant drug rights to Sobi for $1.5 bln upfront

    AstraZeneca took another step to refocus its portfolio on priority projects on Tuesday by selling U.S. rights to a treatment for a serious infant lung infection to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion. Around 130 AstraZeneca staff will transfer to Sobi as the Swedish company, widely known as Sobi, takes over marketing of the drug Synagis in the United States. Sobi also gets the right to participate in AstraZeneca's share of U.S. profits and losses in a follow-on drug for respiratory syncytial virus, called MEDI8897, which AstraZeneca is developing with Sanofi, the companies said.

  • Business Wire4 days ago

    US FDA Accepts Regulatory Submission For LYNPARZA (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-mutated Advanced Ovarian Cancer and Grants Priority Review

    Approval would expand use of AstraZeneca and MSD’s LYNPARZA to patients in the 1st-line setting following platinum-based chemotherapy

  • Business Wire5 days ago

    FARXIGA Significantly Reduced Hospitalization for Heart Failure or CV Death in a Broad Patient Population with Type 2 Diabetes in the Landmark DECLARE-TIMI 58 Trial

    Fewer MACE events observed with FARXIGA vs. placebo, but this finding did not reach statistical significance

  • Reuters5 days ago

    AstraZeneca's diabetes drug curbs heart failure, kidney risks

    The biggest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca's Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients. Diabetics are at increased risk of heart problems, making the CV profile of drugs to treat the condition an important focus for doctors and patients.

  • Financial Times6 days ago

    [$$] AstraZeneca diabetes drug cuts complications

    has markedly reduced the chances of diabetic patients being hospitalised with heart failure, a condition associated with type 2 diabetes. The findings, from a large clinical trial, represent a significant boost for the Anglo-Swedish drugmaker which is striving to meet ambitious revenue targets. Cardio-vascular complications are common in people who contract type 2 diabetes, which has become a major burden on health systems worldwide.

  • Assessing GW Pharmaceuticals’ Year-to-Date Performance
    Market Realist6 days ago

    Assessing GW Pharmaceuticals’ Year-to-Date Performance

    GW Pharmaceuticals (GWPH) is a developer of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenue of $3.46 million in the third quarter, reflecting a 10.2% year-over-year revenue rise in the quarter.

  • Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug
    Zacks7 days ago

    Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug

    Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.

  • ACCESSWIRE7 days ago

    Today's Research Reports on Trending Tickers: AstraZeneca and Bristol-Myers Squibb

    NEW YORK, NY / ACCESSWIRE / November 9, 2018 / U.S. stocks retreated on Thursday after the Fed left interest rates unchanged and signaled that it would continue to tighten monetary policy at a gradual pace. Charlie Ripley, senior investment strategist at Allianz Investment Management said that, “With no press conference or expectation for policy change, most market participants viewed the November FOMC meeting as more of a non-event. “With only minimal changes to the statement the Fed is remaining vague about policy changes going forward and likely giving the committee more optionality in a changing market environment,” he added.

  • Financial Times7 days ago

    [$$] Opinion today: Europe’s plan for Donald Trump

    This article is from today’s FT Opinion email.  Sign up to receive a daily digest of the big issues straight to your inbox. Does Europe have a strategy for coping with Donald Trump? His “America First” ...

  • Investor's Business Daily7 days ago

    AstraZeneca Breaks Out As CEO Predicts 'Sustained Growth' Streak

    AstraZeneca stock broke out Thursday after the pharma reported sales growth, claiming the quarter to be the beginning of continued growth.

  • Thomson Reuters StreetEvents7 days ago

    Edited Transcript of AZN.L earnings conference call or presentation 8-Nov-18 12:00pm GMT

    Q3 2018 AstraZeneca PLC Earnings Call

  • Reuters7 days ago

    AstraZeneca lifts FTSE as U.S. midterm rally fades

    A strong update by heavyweight drugmaker AstraZeneca (AZN.L) lifted Britain's benchmark index above European peers on Thursday as a global rally that followed the midterm U.S. elections faded. The FTSE 100 (.FTSE) rose 0.2 percent and the Euro Stoxx (.STOXXE) fell by 0.4 percent while Wall Street opened in slightly negative territory. AstraZeneca (AZN.L) rose 4 percent after strong demand for its new drugs - especially those for cancer - drove a return to sales growth in the third quarter and the drugmaker said it now anticipated years of sustained improvement.

  • CNBC7 days ago

    AstraZeneca chief says the US drugs market is under pressure and changes are coming

    Pascal Soriot, the CEO of European pharma giant AstraZeneca, believes that now the Democrats have won back control of the House of Representatives, they will "have to work collaboratively with the (President Donald Trump) administration. "We will see what they come up with," he told CNBC's "Squawk Box Europe" on Thursday. AstraZeneca is a biopharmaceutical company with a market capitalization of around $100 billion.

  • AstraZeneca sees years of growth as drug sales turn corner
    Reuters7 days ago

    AstraZeneca sees years of growth as drug sales turn corner

    Strong demand for AstraZeneca's (AZN.L) new drugs -- especially those for cancer -- drove a return to sales growth in the third quarter and the drugmaker said it anticipated years of sustained improvement and rising profit margins. Product sales in the three months rose 8 percent, or 9 percent in constant currencies, which is the benchmark AstraZeneca uses for measuring the return to growth that it has been promising for 2018. It is the first quarter of sustainable product sales growth since 2014 and shares in the group, which resisted a takeover bid by Pfizer (PFE.N) in 2014, rose more than 5 percent to hit a record high of 61.85 pounds on Thursday.

  • AstraZeneca's (AZN) Q3 Earnings Beat, New Drugs Drive Sales
    Zacks7 days ago

    AstraZeneca's (AZN) Q3 Earnings Beat, New Drugs Drive Sales

    AstraZeneca (AZN) beats earnings and sales estimates in the third quarter and maintains previously issued outlook for 2018. AstraZeneca's newer medicines sales rise 86% in the quarter.

  • Associated Press7 days ago

    Astrazeneca: 3Q Earnings Snapshot

    The Cambridge, Britain-based company said it had profit of 34 cents per share. Earnings, adjusted for amortization costs and restructuring costs, came to 71 cents per share. The results topped Wall Street ...